Revenue fell 18% year-over-year due to lower Vimab BESS sales, with net loss widening to -30.9 MSEK. Cash flow was negative but bolstered by a 21 MSEK share issue, and major battery system orders are expected to drive future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.